Establishing the Competitive Counterflow Assay for OATP1B1 and OATP1B3
Miki Katuwal,Regina Schnegelberger,Elliott Wityk,Melissa Ruggiero,Bruno Hagenbuch
DOI: https://doi.org/10.1096/fasebj.30.1_supplement.935.5
2016-04-01
The FASEB Journal
Abstract:OATP1B1 and OATP1B3 are two important drug uptake transporters expressed in human hepatocytes. They mediate the uptake of numerous drugs and other compounds and multiple inhibitors have been identified. However, it has also been suggested that these inhibitors may act as substrates for OATPs. Therefore, we wanted to establish the competitive counterflow assay described by Harper and Wright ( Am J Physiol Renal Physiol 2013; 304:F56–67 ) for OATP1B1 and OATP1B3 with the model substrate estradiol‐17β‐glucuronide (E17βG). This assay should allow to identify compounds that are able to exchange for an OATP substrate such as [ 3 H]‐E17βG that was used to preload OATP expressing CHO cells. CHO cells stably expressing either OATP1B1 or OATP1B3 were used and time dependent uptake of 10nM [ 3 H]‐E17βG was determined on 96‐well plates. Uptake reached a steady‐state plateau at 2 hours and addition of unlabeled E17βG to the extracellular medium at this time triggered time and concentration dependent efflux of [ 3 H]‐E17βG from the preloaded cells, indicating that extracellular E17βG exchanged for intracellular [ 3 H]‐E17βG. This assay was then used to test whether several known OATP substrates would also lead to [ 3 H]‐E17βG efflux, indicating that they are exchanged for the intracellular substrate. After preloading the cells with [ 3 H]‐E17βG, addition of known substrates such as E17βG, estrone‐3‐sulfate, bromosulfophthalein, taurocholate, and rifampicin to the extracellular medium indeed resulted in [ 3 H]‐E17βG efflux, confirming that OATP1B1 and OATP1B3 handle their substrates as exchangers. As negative controls we used glucose, glutamic acid, ouabain and metformin which did not result in [ 3 H]‐E17βG efflux. We then began testing known OATP inhibitors to see whether they would trigger [ 3 H]‐E17βG efflux, and thus would be OATP substrates. Among the tested inhibitors, many resulted in [ 3 H]‐E17βG efflux from both OATP1B1 and OATP1B3 expressing CHO cells, and thus seem to be substrates. These included bromocryptine, cyclosporine A, DIDS, indomethacin, ketoconazole, reserpine, and salinomycin. A few, including berberine, erythromycin, gliquidone, nifedipine, and paranitrosaniline seem to be substrates only for OATP1B1. Thus, because the tested substrates do not need to be radiolabeled and the CCF assay can be performed on 96‐well plates, this is a good screening tool to identify OATP inhibitors that are transported substrates. Support or Funding Information This work was supported by the National Institute of Health Grants R01‐GM077335 and P20‐GM103549‐07.
cell biology,biochemistry & molecular biology,biology